Casdorph, H.R. , "Treatment of Hypercholesteremia with Cholestyramine ," Circulation, Vol 36, No. 4, Supplement No. 2-6, October 1967.
4.
Casdorph, H.R. , "Safe Uses of Cholestyramine," Ann. Int. Med., Vol. 72: 759-760, May 1970 .
5.
Casdorph, H.R. , "Treatment of the Hyperlipidemic States with Special Emphasis on the Place of Cholestyramine in Therapy," Angiology, Vol. 21, No. 10-654-660, November 1970.
6.
Casdorph, H.R. , "Management of Excess Serum Lipid," N. Egl. J. Med., Vol. 284: 1103, May 13, 1971.
7.
Casdorph, H.R., Cholestyramine in "Treatment of the Hyperlipidemic States,"H. R. Casdorph, Ed., Charles C. Thomas, Publisher, Springfield, Illinois, 1971.
8.
Casdorph, H.R., "Ten Years Experience with Cholestyramine in the Treatment of Hyperlipidemias ." Third International Symposium on Atherosclerosis , October 27, 1974, W. Berlin.
9.
Grundy, S.M. , Ahrens, Jr., E.H. and Salen, G., "Interruption of the enterohepatic circulation of bile acids in man: Comparative effects of cholestyramine and ileal exclusion on cholesterol metabolism," J. Lb. Clin. Med., Vol. 78, No. 1, July 1971.
10.
Glueck, C.J. , Ford, Jr., S., Scheel, D. and Steiner, P., "Colestipol and Cholestyramine Resin," J.A.M.A., Vol 222, No. 6, November 1972.
11.
Nazir, D.J. , Horlick, L., Kudchodkar , B.J. and Sodhi, H.S., "Mechanisms of Action of Cholestyramine in the Treatment of Hypercholesterolemia," Circulation, Vol. XLVI, July 1972 .
12.
E. Van Handel and D.E. Zilversmit, J. Lab. & Clin. Med.50, 152 ( 1957) modified for use on the Autoanalyzer.
13.
S. Natelson , Microtechniques of Clinical Chemistry, 2nd ed., Charles C. Thomas, Springfield, Illinois1961, p. 158.
14.
Hyland Clotek™System for Determining Prothrombin Time (one stage protime).
15.
West, R.J. and Lloyd, J.K., "Use of Cholestyramine in Treatment of Children with Familial Hypercholesterolaemia ," Arch. Dis. Child., Vol.48: 370-4, 1973.
16.
Folate blood levels performed by Bio-Science Laboratories, Van Nuys, California.
17.
Levy, R.I. et al, "Cholestyramine in Type II Hyperlipoproteinemia-A Double-Blind Trial," Ann. Int. Med., Vol. 79, No. 1, 15-58, July 1973.
18.
Physicians' Deck Reference, 28th edition. Medical Economics Company, Oradell, New Jersey, 1974. Questran R (Cholestyramine) , pp. 986-987.
19.
Casdorph, H.R.Cholestyramine and Ion Exchange Resins In Lipid Pharmacology, R. Paoletti and C. Glueck (Editors) Academic Press (In Press) New York, New York.
20.
Caldwell, J.H. , Greenberger, N.J.: Cholestyramine enhances digitalis excretion and protects against lethal intoxication. J. Clin. Invest. , 49: 16A, 1970.
21.
Caldwell, J.H. , Bush, C.A., and Greenberger , N.J.: Interruption of the enterohepatic circulation of digitoxin by cholestyramine. J. Clin. Invest., 50: 2638-2644, 1971 .
22.
Bazzano, G. , and Bazzano, G.S.: Colestipol and Cholestyramine in the Treatment of Digitalis Intoxication. Clin. Res.,19: 305, 1971.
23.
Bazzano, G. , and Bazzano, G.S.: Digitalis intoxication: treatment with a new steroid-binding resin. J.A.M.A., 220: 828-830, 1972.